CCP authorizes Citi Pharma’s proposed acquisition of 100% of Pakheim International Pharma

Material Disclosure

Citi Pharma Limited announced that the Competition Commission of Pakistan has authorized its proposed acquisition of the entire shareholding of Pakheim International Pharma (Private) Limited, finding that the transaction does not raise competition concerns. Completion remains subject to the Share Purchase Agreement and applicable legal, regulatory and other formalities.

Key Findings

  • CCP order dated October 9, 2026 authorizes the proposed acquisition under Section 31(1)(d)(i) of the Competition Act, 2010.
  • The proposed transaction is for 100% of Pakheim International Pharma (Private) Limited.
  • The acquisition will proceed in accordance with a Share Purchase Agreement dated May 6, 2026, subject to completion formalities.
  • Citi Pharma said it will make further disclosures as relevant transaction milestones are completed.

Disclosure Details

Entities Involved
Citi Pharma Limited, Pakheim International Pharma (Private) Limited, Competition Commission of Pakistan
Amount
Acquisition of 100% shareholding; purchase price not disclosed
Approvals Required
Competition Commission of Pakistan authorization received, Applicable legal, regulatory and other formalities remain
Impact
Regulatory authorization clears the competition review stage for Citi Pharma’s proposed acquisition of Pakheim International Pharma; completion is still subject to remaining formalities.
Risks
Transaction completion is not confirmed and remains subject to the Share Purchase Agreement and applicable legal, regulatory and other formalities.
⚡

Highlights summarize the key points from the company's official PSX filing. View the original filing for the complete details before making financial decisions.

More CPHL announcements

Built for PSX investors

Every filing.Summarised.

Key findings from every PSX announcement, right beside live prices and your portfolio.

Investify company announcements with result figures and filing highlights
Investify announcement summary with key findings from a PSX filing